Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DBV Technologies (DBVT) Change in Receivables (2016 - 2021)

DBV Technologies (DBVT) reported Change in Receivables of $24000.0 for Q4 2021, down 75.0% year-over-year from $96000.0 in Q4 2020, and up 2300.0% on a QoQ basis from $1000.0 in Q3 2021.

DBV Technologies (DBVT) has 5 years of Change in Receivables data on file, last reported at $24000.0 in Q4 2021.

  • Quarterly Change in Receivables fell 75.0% year-over-year to $24000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $24000.0 (up 101.15% YoY) and the FY2021 annual result came in at -$2.2 million, down 203.86% from the prior year.
  • Change in Receivables improved to $24000.0 in Q4 2021 per DBVT's latest filing, from $1000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.0 million in Q3 2020 and bottomed at -$2.1 million in Q1 2021.
  • The 4-year median for Change in Receivables is $19791.9 (2017), against an average of $129871.4.
  • The widest annual swing landed in 2017, when Change in Receivables jumped 210.36%; it then plunged 199.24% in 2018.
  • Tracing DBVT's Change in Receivables over 4 years: stood at $1.5 million in 2017, then plunged by 199.24% to -$1.5 million in 2018, then surged by 106.49% to $96000.0 in 2020, then tumbled by 75.0% to $24000.0 in 2021.
  • Per Business Quant, the three latest DBVT Change in Receivables figures stand at $24000.0 (Q4 2021), $1000.0 (Q3 2021), and -$74000.0 (Q2 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 208,524.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -39.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -1.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 110.42 Mn
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 24,000.00
Dec 31, 2021 24,000.00
Sep 30, 2021 1,000.00
Sep 30, 2021 1,000.00
Jun 30, 2021 -74,000.00
Jun 30, 2021 -74,000.00
Mar 31, 2021 -2.10 Mn
Mar 31, 2021 -2.10 Mn
Dec 31, 2020 96,000.00
Dec 31, 2020 96,000.00
Sep 30, 2020 1.98 Mn
Sep 30, 2020 1.98 Mn
Dec 31, 2018 -1.48 Mn
Dec 31, 2018 -1.48 Mn
Sep 30, 2018 1.47 Mn
Sep 30, 2018 1.47 Mn
Jun 30, 2018 3,580.33
Jun 30, 2018 3,580.33
Dec 31, 2017 1.49 Mn
Dec 31, 2017 1.49 Mn
Jun 30, 2017 19,791.89
Jun 30, 2017 19,791.89
Dec 31, 2016 -1.35 Mn
Dec 31, 2016 -1.35 Mn